What scRNA sequencing taught us about MGMT expression in glioblastoma
Abstract
IntroductionThe promoter methylation status of O-6-methylguanine-DNA methyltransferase (MGMTp) is an established predictive and prognostic marker in GBM. Previous studies showed that the expression of MGMT based on immunohistochemistry was variable and lacked association with survival. This in part is because non-tumor cells including endothelial cells and macrophages express MGMT. Advanced technologies such as single-cell RNA (scRNA) sequencing have helped to elucidate the cellular composition of cancer and its microenvironment. scRNA sequencing allows to assess gene expression level in tumor cells specifically. MethodsWe used publicly available data from two recent GBM scRNA studies that included MGMTp methylation status data for patients to explore and uncover details about MGMT expression at the single-cell level: CPTAC (13 primary samples) and Neftel (20 primary samples). ResultsIn the CPTAC study, MGMT expression ranged from 0.19%-1.43% in the MGMTp methylated group (median 0.82%), and from 2.17%-28.36% in the MGMTp unmethylated group (median 5.7%). It therefore appears that 2% is a reasonable expression cutoff to predict the MGMTp methylation status based on scRNA data. In the Neftel study, MGMT expression ranged from 0-1.26% in the MGMTp methylated group (median 0.59%), and from 0.3-27.67% in the MGMTp unmethylated group (median 12.44%). Three unmethylated samples (out of 16) did not follow the 2% rule. It remains unclear if this is due to technical inaccuracies as the Neftel paper did not specify the method used to detect MGMTp methylation or even mere typos. Alternatively, could it be that truly MGMTp unmethylated samples can have low MGMT expression? Could this explain why some unmethylated MGMTp GBM patients surpass the expected survival? Interestingly, gene set enrichment analysis shows that MGMT expressing cells are enriched with mesenchymal genes, whereas MGMT negative cells are enriched with proneural genes. ConclusionFewer than 2% of GBM cells express MGMT when MGMTp is methylated.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.41
- Field percentile
- top 44%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma
L. Zhao, J. Zhang, … P. Zhao·Frontiers in Cell and Developmental BiologyPeer-reviewed·Feb 5, 2021
- A draft single-cell atlas of human glioblastoma reveals a single axis of phenotype in tumor-propagating cells.
Sören Müller, Elizabeth Di Lullo, … Aaron Diaz·bioRxiv·Jul 26, 2018
- Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells
R. Weber, M. Weller, … F. Vasella·bioRxiv·Sep 21, 2023
- Glioblastoma recurrence and the role of MGMT promoter methylation
Katie Storey, Kevin Leder, … Jasmine Foo·bioRxiv·May 9, 2018
- Sensitivity to temozolomide of cell lines derived from brain tumours and melanomas: relationship to MGMT gene expression
Bruce C. Baguley, Wayne R. Joseph, … Elaine S Marshall·bioRxiv·Nov 30, 2024
- Analysis of gliomas DNA methylation: Assessment of pre-analytical variables.
Karol Bomsztyk, Daniel Mar, … Robert Rostomily·Laboratory InvestigationPeer-reviewed·Oct 18, 2024